MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202521134560 A) filed by Dr Snehal Bansod; Dr Aafreen Aftab; Dr Nisha Chandrakar; Dr Varada; Dr Saloni Parganiha; Dr Himanshi Sachdev; Dr Nitin Kayande; Dr. Chetna Shukla; Dr. Pratyush Shrivastava; and Dr. Bushra Ameen Tigala, Bhilai, Chattisgarh, on Dec. 31, 2025, for 'cost-effective titanium foil for guided bone regeneration.'

Inventor(s) include Dr Snehal Bansod; Dr Aafreen Aftab; Dr Nisha Chandrakar; Dr Varada; Dr Saloni Parganiha; Dr Himanshi Sachdev; Dr Nitin Kayande; Dr. Chetna Shukla; Dr. Pratyush Shrivastava; and Dr. Bushra Ameen Tigala.

The application for the patent was published on Feb. 13, under issue no. 07/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to a cost-effective titanium foil for guided bone regeneration procedures in dental and maxillofacial surgery. The invention comprises a thin, malleable, biocompatible barrier membrane manufactured from Grade 2 commercially pure titanium with standardized thickness of 0.1 millimeters and dimensions of 25 millimeters by 25 millimeters. The titanium foil provides mechanically stable barrier function preventing soft tissue invasion into bone defects while maintaining space for osteogenic cell proliferation and new bone formation. The foil exhibits superior manipulability allowing intraoperative contouring to various bone defect morphologies, sufficient rigidity to withstand soft tissue pressure and masticatory forces, and excellent biocompatibility ensuring favorable tissue integration. The invention is applicable across diverse clinical scenarios including periodontal defects, ridge augmentation, simultaneous implant placement with bone grafting, and large osseous defect reconstruction. The cost-effectiveness derives from optimized manufacturing processes, standardized dimensions, simplified surgical protocols, and elimination of custom fabrication requirements, making advanced bone regeneration techniques accessible to broader patient populations while maintaining equivalent clinical efficacy and safety compared to existing expensive titanium barrier systems."

Disclaimer: Curated by HT Syndication.